Advanced breast cancer metastasized in the brain: treatment standards and innovations

Klaas, Elizabeth; Sung, Eric; Azizi, Esaan; Martínez, Melanie; Barpujari, Arnav; Roberts, Jeffery J.; Lucke‐Wold, Brandon

doi:10.20517/2394-4722.2022.125

Cited by 3 publications

(6 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNBC lacks a standardized treatment approach. As the current therapies for TNBC lack the effectiveness to improve patients’ survival, it is crucial to develop novel treatments ( 11 ). Personalized immunotherapy could also be considered for the TNBC patients with LM, but the effectiveness needs to be supported by more study in the future ( 12 ).…”

Section: Discussionmentioning

confidence: 99%

Leptomeningeal metastasis of breast cancer during neo-adjuvant chemotherapy in a 38-year-old woman: a case report

Jin,

Lu,

Zhang

et al. 2024

AME Case Rep

View full text Add to dashboard Cite

Background Breast cancer accounts for 5% of the population who develop central nervous system metastasis, which is only second to the lung cancer. Breast cancer metastasis to the brain including parenchymal brain metastasis (BM) and leptomeningeal metastasis (LM). Compared with BM, LM is a more rare but aggressive metastatic diagnosis with poor outcome. Case Description We reported a 38-year-old woman presented to the neurology department due to progressive headache for 1 month, accompanied with dizziness, nausea, vomiting and neck pain. During hospitalization, she experienced paroxysmal loss of consciousness twice. Five months prior to this visit, her first visit was diagnosed with breast cancer on the right side which was of triple-negative subtype and with homolateral axillary lymph node involvement by biopsy. After the clinician assessment she had received six cycles of TCb (docetaxel/carboplatin) neo-adjuvant chemotherapy. During the period of neo-adjuvant chemotherapy, she did not report the presence of severe neurological symptoms. Twenty days ago, she underwent right breast-conserving surgery and the postoperative evaluation was ypT1N3M0 stage and Miller-Payne grade 2. Head computed tomography (CT) scan and contrast-enhanced magnetic resonance imaging (MRI) didn’t find typical brain imaging changes. No other signs of metastasis were seen in the CT examinations of the patient’s chest and abdomen. Finally, lumbar puncture with cerebrospinal fluid (CSF) analysis showed the presence of malignant cells. Given the patient’s clinical history and new neurologic symptoms, the diagnosis was LM from breast cancer. Various treatment modalities including intrathecal thiotepa, oral temozolomide (TMZ) and whole-brain radiation therapy (WBRT) had been used, but none of them showed significant benefit for survival. Conclusions Breast cancer metastasis to the brain, especially LM, should be given sufficient vigilance and attention at the beginning of the diagnosis and treatment, particularly in triple-negative breast cancer patients who are at high risk. Symptoms of LM may be masked by the chemotherapy adverse effects. The results of MRI and CT may show negative results, thus lumbar puncture with CSF should be done promptly if LM is highly suspected in clinical practice. Early prevention, early detection and timely treatment are crucial according to the poor prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Leptomeningeal metastasis of breast cancer during neo-adjuvant chemotherapy in a 38-year-old woman: a case report

Jin,

Lu,

Zhang

et al. 2024

AME Case Rep

View full text Add to dashboard Cite

show abstract

“…The number of gained variants ranged from 44 (HCC38 r DOX 40 ) to 381 (HCC38 r GEM 20 ), of de novo variants from 31 (HCC38 r DOX 40 ) to 225 (MDA-MB-468 r PCL 20 ), of not-called variants from 88 (HCC38 r GEM 20 and HCC1806 r DOX 12.5 ) to 345 (MDA-MB-468 r PCL 20 ), of lost variants from 129 (HCC38 r GEM 20 ) to 398 (MDA-MB-468 r PCL 20 ), and of shared variants from 128 (MDA-MB-468 r PCL 20 ) to 368 (HCC38 r GEM 20 ) (Fig. 2B-2D, SupFile.3).…”

Section: Characterization Of the Cell Line Panel By Whole Exome Seque...mentioning

confidence: 99%

“…The project cell line panel consists of the parental TNBC cell lines MDA-MB-468, HCC38, and HCC1806 and their sublines adapted to grow in the presence of cisplatin, doxorubicin, eribulin, paclitaxel, gemcitabine, or 5-fluorouracil, drugs from drug classes that are used for the treatment of this cancer type (Fig. 1A, SupFile.1) [20][21][22][23][24][25][26] . Drug-resistant sublines were established by continuous exposure to stepwise increasing drug concentrations as previously described 17 .…”

Section: Project Cell Line Panelmentioning

confidence: 99%

“…Between 186 (HCC38 r DOX 40 ) and 739 (HCC38 r GEM 20 ) DNA sequence variants were detected in the drug-adapted sublines that differed from the respective parental cell lines (SupFig.2A, SupFile.2). Missense variants were most common, followed by synonymous variants (SupFig.2B).…”

Section: Characterization Of the Cell Line Panel By Whole Exome Seque...mentioning

confidence: 99%

“…There were noticeable differences in the overlaps between de novo variants of the sublines of the individual parental cell lines. For example, only three de novo variants were shared between HCC38 r CDDP 3000 (out of 98 in total, 3.1%) and HCC38 r PCL 2.5 (out of 92 in total, 3.3%), while 53 variants were shared between HCC38 r ERI 10 (out of 131 in total, 40.5%) and HCC38 r GEM 20 (out of 203 in total, 26.1%) (Fig. 3C, SupFig.3B).…”

Section: Analysis Of the Distribution Of De Novo Variantsmentioning

confidence: 99%

See 2 more Smart Citations

Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors

Grimsley,

Antczak,

McLaughlin

et al. 2024

Preprint

View full text Add to dashboard Cite

Here, we introduce a novel set of drug-adapted triple-negative breast cancer (TNBC) cell lines consisting of the parental cell lines MDA-MB-468, HCC38, and HCC1806 and their sublines adapted to cisplatin, doxorubicin, eribulin, paclitaxel, gemcitabine, or 5-fluorouracil. Whole exome sequencing in combination with the analysis of TCGA-derived patient data resulted in the identification of 135 biomarker candidates for the guidance of personalized TNBC therapies for further investigation, including 58 novel ones that had not been associated with drug resistance before. The analysis of exome sequencing data showed remarkably few overlaps among the resistant sublines, suggesting that each resistance formation process follows an individual, unpredictable route. This complexity was confirmed by cancer cell line drug sensitivity profiles to cytotoxic anti-cancer drugs and DNA damage repair inhibitors. Drug-adapted sublines of the same parental cell line and sublines adapted to the same drug substantially differed in their drug response patterns. Cross-resistance levels were lowest for the CHK2 inhibitor CCT241533, the PLK1 inhibitor SBE13, and the RAD51 recombinase inhibitor B02, making CHK2, PLK1, and RAD51 promising drug targets for therapy-refractory TNBC. In conclusion, we present novel preclinical models of acquired drug resistance in TNBC and 58 novel candidate biomarkers for further investigation. Whole exome data and drug sensitivity profiles showed that each cancer cell line adaptation process follows an unpredictable route, which reflects recent findings on cancer cell evolution in patients, supporting the relevance of drug-adapted cancer cell lines as preclinical models of acquired resistance.

show abstract

Current Management of Brain Metastases in Breast Cancer

Güler,

Arslan,

Dağ

2024

Indian J Surg

View full text Add to dashboard Cite

Advanced breast cancer metastasized in the brain: treatment standards and innovations

Cited by 3 publications

References 58 publications

Leptomeningeal metastasis of breast cancer during neo-adjuvant chemotherapy in a 38-year-old woman: a case report

Leptomeningeal metastasis of breast cancer during neo-adjuvant chemotherapy in a 38-year-old woman: a case report

Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors

Current Management of Brain Metastases in Breast Cancer

Contact Info

Product

Resources

About